HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity.
- Author:
Yan XU
1
;
Hao CHENG
;
Ke-Jia ZHAO
;
Ke-Jian ZHU
;
Xing ZHANG
Author Information
1. Sir Run Run Shaw Hospital, Zhejiang University Medical School, Hangzhou 310016, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Calreticulin;
genetics;
Female;
Human papillomavirus 6;
immunology;
Mice;
Mice, Inbred C57BL;
Neovascularization, Pathologic;
prevention & control;
Oncogene Proteins, Viral;
genetics;
Papillomavirus Infections;
therapy;
Papillomavirus Vaccines;
immunology;
Recombinant Fusion Proteins;
genetics;
Vaccines, DNA;
immunology
- From:
Chinese Journal of Virology
2007;23(6):466-470
- CountryChina
- Language:Chinese
-
Abstract:
This paper was to study the angiogenic inhibitory effect and the potential antitumor effect of the constructed recombinant DNA vaccine CRT/HPV6bE7 in vivo. The C57BL/6 mice were vaccinated respectively with recombinant CRT/HPV6bE7 DNA plamids. The inhibitory effects on angiogenesis of generated vaccines in vivo were evaluated by a bFGF-induced angiogenesis assay using the Matrigel kit. To investigate the potential antitumor effect, the mean tumor weights, sizes and tumor appearing times were measured in C57BL/6 mice treated with HPV6bE7-expressing B16 cells. The results indicated that the recombinants CRT180/HPV6bE7 and CRT180 showed strong anti-angiogenic effects in bFGF-induced angiogenesis in vivo. Moreover, CRT180/HPV6bE7 and CRT180 DNA vaccines could significantly inhibit the tumor growth in tumor challenge experiment, and CRT180/HPV6bE7 was superior to other vaccines in delaying tumor formation time, limiting tumor size and weight in tumor protection experiment. In conclusion, recombinant CRT180/HPV6bE7 DNA could elicit a most efficient anti-angiogenic effect and inhibit tumor growth in mice inoculated with DNA vaccines. The antiangiogenic activity of CRT were suggested residing in a domain between CRT 120-180 aa.
